Randomized controlled trials: What are they and who needs them?

Periodontology 2000

Volumn 59, Issue 1, 2012, Pages 14-31

  Pihlstrom, Bruce L ^a   Curran, Alice E ^a   Voelker, Helen T ^a   Kingman, Albert ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLASSIFICATION; DENTAL PROCEDURE; DENTAL RESEARCH; EVIDENCE BASED DENTISTRY; HUMAN; INFORMED CONSENT; METHODOLOGY; PATIENT SAFETY; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); STANDARD; TREATMENT OUTCOME;

DENTAL CARE; DENTAL RESEARCH; EVIDENCE-BASED DENTISTRY; HUMANS; INFORMED CONSENT; PATIENT SAFETY; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 84859823340     PISSN: 09066713     EISSN: 16000757     Source Type: Journal    
DOI: 10.1111/j.1600-0757.2011.00439.x     Document Type: Article

References (73)

1. Ali MW, Siddiqui O. Multiple imputation compared with some informative dropout procedures in the estimation and comparison of rates of change in longitudinal clinical trials with dropouts. J Biopharm Stat 2000: 10: 165-181.
2. Altman DG. Endorsement of the CONSORT statement by high impact medical journals: survey of instructions for authors. BMJ 2005: 330: 1056-1057.
3. American Dental Association Center for Evidence-Based Dentistry. 2011 ADA Clinical Recommendations Handbook. [accessed October 2011].
4. Auleley GR, Giraudeau B, Baron G, Maillefert JF, Dougados M, Ravaud P. The methods for handling missing data in clinical trials influence sample size requirements. J Clin Epidemiol 2004: 57: 447-453.
5. Balas EA, Boren SA. Managing clinical knowledge for health care improvement. In: Bemmel J, McCray AT, editors. Yearbook of Medical Informatics 2000: Patient-Centered Systems. Stuttgart, Germany: Schattauer Verlagsgesellschaft mbH, 2000: 65-70.
6. Barnes SA, Lindborg SR, Seaman JW Jr. Multiple imputation techniques in small sample clinical trials. Stat Med 2006: 25: 233-245.
7. Barnett ML, Pihlstrom BL. Methods for enhancing the efficiency of dental/oral health clinical trials: current status, future possibilities. J Dent Res 2004: 83: 744-750.
8. Beck J, Garcia R, Heiss G, Vokonas PS, Offenbacher S. Periodontal disease and cardiovascular disease. J Periodontol 1996: 67: 1123-1137.
9. Becker W, Becker BE, Caffesse R, Kerry G, Ochsenbein C, Morrison E, Prichard J. A longitudinal study comparing scaling, osseous surgery, and modified Widman procedures: results after 5years. J Periodontol 2001: 72: 1675-1684.
10. Blackwelder WC. Current issues in clinical equivalence trials. J Dent Res 2004: 83 (Spec C): C113-C115.
11. Branson RD, Davis K Jr, Butler KL. African Americans' participation in clinical research: importance, barriers, and solutions. Am J Surg 2007: 193: 32-39; discussion 40.
12. Brook RH, Lohr KN. Efficacy, effectiveness, variations, and quality. Boundary-crossing research. Med Care 1985: 23: 710-722.
13. Current Controlled Trials. [accessed October 2011].
14. Dickersin K, Rennie D. Registering clinical trials. JAMA 2003: 290: 516-523.
15. SCT Working Group on Data Monitoring, Dixon DO, Freedman RS, Herson J, Hughes M, Kim K, Silverman MH, Tangen CM. Guidelines for data and safety monitoring for clinical trials not requiring traditional data monitoring committees. Clin Trials 2006: 3: 314-319.
16. Downing DG. Biomarkers and surrogate endpoints: clinical research and applications (2000). Proceedings of an NIH-FDA Conference, April 15-16, 1999, Bethesda, MD. USA. 2000: 3.
17. Downing DG. Biomarkers and surrogate endpoints: clinical research and applications (2000). Proceedings of an NIH-FDA Conference, April 15-16, 1999, Bethesda, MD. USA. 2000: 6-9.
18. Emanuel EJ, Schnipper LE, Kamin DY, Levinson J, Lichter AS. The costs of conducting clinical research. J Clin Oncol 2003: 21: 4145-4150.
19. Friedman LM, Furberg CD, DeMets DL. Data collection and quality control. In: Fundamentals of clinical trials. New York: Springer-Verlag, 1998: 156-159.
20. Friedman LM, Furberg CD, DeMets DL. Introduction to clinical trials. In: Fundamentals of clinical trials. New York: Springer-Verlag, 1998: 2.
21. Friedman LM, Furberg CD, DeMets DL. Multicenter trials. In: Fundamentals of clinical trials. New York: Springer-Verlag, 1998: 346.
22. Friedman LM, Furberg CD, DeMets DL. The randomization process. In: Fundamentals of clinical trials. New York: Springer-Verlag, 1998: 61-81.
23. Friedman LM, Furberg CD, DeMets DL. Subgroup analysis. In: Fundamentals of clinical trials. New York: Springer-Verlag, 1998: 304-306.
24. Friedman LM, Furberg CD, DeMets DL. What is the question? In: Fundamentals of clinical trials, 3rd edn. New York: Springer-Verlag, 1998: 16-29.
25. Gottlieb MS, Schroff R, Schanker HM, Weisman JD, Fan PT, Wolf RA, Saxon A. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N Engl J Med 1981: 305: 1425-1431.
26. Gotzsche PC. Lessons from and cautions about noninferiority and equivalence randomized trials. JAMA 2006: 295: 1172-1174.
27. Greiner AC, Knebel E. Health professions education: a bridge to quality. Washington DC: National Academy Press, 2003.
28. Harvard University FoM. Faculty Policies on Integrity in Science. [accessed October 2011].
29. Heitjan DF. Causal inference in a clinical trial: a comparative example. Control Clin Trials 1999: 20: 309-318.
30. International Committee of Medical Journal Editors. Uniform requirements for manuscripts submitted to biomedical journals: writing and editing for biomedical publication. [accessed October 2011].
31. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Drug safety. [accessed October 2011].
32. Jadad AR, Rennie D. The randomized controlled trial gets a middle-aged checkup. JAMA 1998: 279: 319-320.
33. Laster LL, Johnson MF. Non-inferiority trials: the 'at least as good as' criterion. Stat Med 2003: 22: 187-200.
34. Meinert CL. Masked monitoring in clinical trials - blind stupidity? N Engl J Med 1998: 338: 1381-1382.
35. Michalowicz BS, Diangelis AJ, Novak MJ, Buchanan W, Papapanou PN, Mitchell DA, Curran AE, Lupo VR, Ferguson JE, Bofill J, Matseoane S, Deinard AS Jr, Rogers TB. Examining the safety of dental treatment in pregnant women. J Am Dent Assoc 2008: 139: 685-695.
36. Michalowicz BS, Hodges JS, DiAngelis AJ, Lupo VR, Novak MJ, Ferguson JE, Buchanan W, Bofill J, Papapanou PN, Mitchell DA, Matseoane S, Tschida PA; OPT Study. Treatment of periodontal disease and the risk of preterm birth. N Engl J Med 2006: 355: 1885-1894.
37. National Academy of Sciences. Authorship Practices. On being a scientist: responsible conduct in research. Washington, DC: National Academy Press, 1995.
38. Neaton JD, Duchene AG, Svendsen KH, Wentworth D. An examination of the efficiency of some quality assurance methods commonly employed in clinical trials. Stat Med 1990: 9: 115-123; discussion 124.
39. NIH DHHS Office of Extramural Research. Glossary and acronym list. [accessed October 2011].
40. OCEBM Levels of Evidence Working Group. The Oxford 2011 levels of evidence. Oxford Centre for Evidence-Based Medicine. [accessed October 2011].
41. Offenbacher S, Katz V, Fertik G, Collins J, Boyd D, Maynor G, McKaig R, Beck J. Periodontal infection as a possible risk factor for preterm low birth weight. J Periodontol 1996: 67: 1103-1113.
42. Pihlstrom B. Issues in the evaluation of clinical trials of periodontitis: a clinical perspective. J Periodontal Res 1992: 27: 433-441.
43. Pihlstrom BL. Measurement of attachment level in clinical trials: probing methods. J Periodontol 1992: 63: 1072-1077.
44. Pihlstrom BL, Barnett ML. Design, operation, and interpretation of clinical trials. J Dent Res 2010: 89: 759-772.
45. Pihlstrom BL, Ortiz-Campos C, McHugh RB. A randomized four-year study of periodontal therapy. J Periodontol 1981: 52: 227-242.
46. Pocock SJ. The size of a clinical trial. In: Clinical trials: a practical approach. Hoboken, NJ: John Wiley & Sons Ltd, 2002: 123-141.
47. Preparing Data Collection Forms. Spilker B. Guide to Clinical Trials. 262-271. 91. New York: Raven Press.
48. Prochaska JO, Evers KE, Prochaska JM, Van Marter D, Johnson JL. Efficacy and effectiveness trials: examples from smoking cessation and bullying prevention. J Health Psychol 2007: 12: 170-178.
49. Rosenbaum PR. Observational studies. New York: Springer-Verlag, 2002.
50. Ross S. Composite outcomes in randomized clinical trials: arguments for and against. Am J Obstet Gynecol 2007: 196: 119.e1-119.e6.
51. Rothman KJ. Epidemiology: an introduction. New York: Oxford, 2002.
52. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004: 62: 527-534.
53. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. J Clin Epidemiol 2010: 63: 834-840.
54. Shelby-James TM, Abernethy AP, McAlindon A, Currow DC. Handheld computers for data entry: high tech has its problems too. Trials 2007: 8: 5.
55. Ship JA, Curro FA, Caufield PW, Dasanayake AP, Lindblad A, Thompson VP, Vena D. Practicing dentistry using findings from clinical research: you are closer than you think. J Am Dent Assoc 2006: 137: 1488-1490, 1492, 1494.
56. Solis AC, Lotufo RF, Pannuti CM, Brunheiro EC, Marques AH, Lotufo-Neto F. Association of periodontal disease to anxiety and depression symptoms, and psychosocial stress factors. J Clin Periodontol 2004: 31: 633-638.
57. Spilker B. Interpretation of adverse reactions. Guide to clinical trials. New York: Raven Press, 1991: 565-599.
58. Tonks A. Registering clinical trials. BMJ 1999: 319: 1565-1568.
59. Turan FN, Senocak M. Evaluating "superiority", "equivalence" and "non-inferiority" in clinical trials. Ann Saudi Med 2007: 27: 284-288.
60. U.S. Food and Drug Administration. Draft guidance for industry: non-inferiority clinical trials. [accessed October 2011].
61. U.S. Food and Drug Administration. Guidance for Clinical Trials Sponsors: Establishment and Operation of Clinical Trials Monitoring Committees. [accessed October 2011].
62. U.S. Food and Drug Administration. What is a serious adverse event? [accessed October 2011].
63. U.S. Food and Drug Administration. DHHS Part 46 protection of human subjects. [accessed October 2011].
64. U.S. Food and Drug Administration. Guidance for drug applications. [accessed October 2011].
65. U.S. Food and Drug Administration. Safety reporting. 21CFR312.32. [accessed October 2011].
66. U.S. National Institutes of Health. ClinTrials.gov. [accessed October 2011].
67. Varmus H. Biomarkers and Surrogate Endpoints: Clinical Research and Applications (2000). Proceedings of an NIH-FDA Conference, April 15-16, 1999, Bethesda, MD. USA. 2000: xiii.
68. Ware JH, Antman EM. Equivalence trials. N Engl J Med 1997: 337: 1159-1161.
69. Wilhelmsen L. Role of the Data and Safety Monitoring Committee (DSMC). Stat Med 2002: 21: 2823-2829.
70. Wittes J. Forming your phase III trial's data and safety monitoring board: a perspective on safety. J Investig Med 2004: 52: 453-458.
71. Wood CG, Wei SJ, Hampshire MK, Devine PA, Metz JM. The influence of race on the attitudes of radiation oncology patients towards clinical trial enrollment. Am J Clin Oncol 2006: 29: 593-599.
72. World Health Organization. International Clinical Trials Registry Platform (ICTRP). [accessed October 2011].
73. Wright CC, Sim J. Intention-to-treat approach to data from randomized controlled trials: a sensitivity analysis. J Clin Epidemiol 2003: 56: 833-842.